• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Oncology

Inovio names new chief medical officer

June 27, 2022 By Sean Whooley

Inovio Pharmaceuticals

Inovio (Nasdaq:INO) announced today that it appointed Dr. Michael Sumner as its new chief medical officer (CMO). Sumner will oversee Inovio’s clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, along with regulatory affairs, pharmacovigilance and medical affairs. He will also serve on the company’s executive leadership team and report to […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Oncology, Personnel, Pharmaceuticals Tagged With: Inovio Pharmaceuticals, Personnel, Personnel Moves

Boston Scientific warns on some SpaceOAR systems

March 21, 2022 By Sean Whooley

Boston Scientific

Boston Scientific (NYSE:BSX) has issued an urgent field safety notice in Europe due to potential issues with its SpaceOAR systems. Marlborough, Massachusetts-based Boston Scientific’s SpaceOAR system is an absorbable polyethylene glycol hydrogel spacer for separating the prostate from the rectal wall during radiation treatment for prostate cancer. The SpaceOAR Vue, the next-generation hydrogel spacer, offers enhanced […]

Filed Under: Featured, Hydrogels, Oncology, Radiosurgery, Recalls, Regulatory/Compliance Tagged With: Boston Scientific

First patients enrolled in trial for Boston Scientific’s SpaceOAR Vue hydrogel

February 10, 2022 By Sean Whooley

Boston Scientific

GenesisCare announced today that it enrolled the first patients in a trial for Boston Scientific’s (NYSE:BSX) SpaceOAR Vue hydrogel. Boston Scientific’s SpaceOAR Vue hydrogel will be evaluated in the SABRE trial, sponsored by Boston Scientific, for prostate cancer patients receiving stereotactic body radiation therapy (SBRT). Get the full story at our sister site, MassDevice.

Filed Under: Clinical Trials, Featured, Hydrogels, Oncology Tagged With: Boston Scientific

Dyve Biosciences to collaborate with Moffitt Cancer Center on transdermal buffering agent

February 3, 2022 By Sean Whooley

Dyve Bioscience logo

Dyve Biosciences announced today that it entered into a joint two-year research collaboration with the Moffit Cancer Center. Under the collaboration, Dyve and Moffit will study the former’s systemic buffering agent, DYV800, delivered through the company’s broadly applicable transdermal delivery technology, in various cancer laboratory models. According to a news release, the models through which […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Oncology, Pharmaceuticals Tagged With: dyvebioscience, Moffit Cancer Center

FDA grants breakthrough nod to Zetagen’s metastatic bone cancer treatment

December 1, 2021 By Sean Whooley

Zetagen Logo

Zetagen Therapeutics announced today that it received FDA breakthrough device designation for its ZetaMet cancer treatment technology. Syracuse, New York-based Zetagen designed its ZetaMet (previously known as ZetaFuse) as a synthetic, small-molecule, inductive biologic technology for targeting and resolving metastatic bone lesions while inhibiting future tumor growth and regenerating bone. According to a news release, […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Oncology, Regenerative Medicine, Stem Cells Tagged With: FDA, Zetagen Therapeutics

AbbVie, University of Chicago lengthen oncology research partnership until 2025

November 10, 2021 By Brian Buntz

AbbVie/University of Chicago

AbbVie (NYSE: ABBV) has extended an agreement with the University of Chicago related to collaborative preclinical oncology research. The North Chicago, Illinois–based company and the university are working together on research involving biomarkers and therapeutic applications related to existing AbbVie programs. In the past, the organizations have also explored new drug delivery methods to improve […]

Filed Under: Oncology Tagged With: 3D screening, AbbVie, oncology, tumors, University of Chicago

Merck and Vesselon preclinical study reports dramatic tumor pharmacokinetics findings

September 22, 2021 By Brian Buntz

Merck/Vesselon

Merck & Co. (NSDQ:MRNA) scientists have explored fighting cancer by way of the STING (stimulator of interferon genes)-controlled innate immune pathway. Now, the company has published research in Advanced Therapeutics detailing a preclinical study with its partner Vesselon Inc. that reported impressive pharmacokinetics results related to MSA-1, a STING agonist. The researchers found that low […]

Filed Under: Featured, Oncology, Pharmaceuticals, Technology Tagged With: Keytruda, Merck, MSA-1, oncology, tumor, ultrasound, Vesselon

Boston Scientific touts data from Phase 3 study of selective internal radiation therapy

September 20, 2021 By Sean Whooley

Boston Scientific

Boston Scientific (NYSE:BSX) today touted data from a Phase 3 clinical trial of its TheraSphere Y-90 glass microspheres treatment. In the trial, the TheraSphere treatment successfully met both primary endpoints, including progression-free survival (PFS) and hepatic progression-free survival (hPFS) in patients with metastatic colorectal cancer (mCRC) of the liver. Marlborough, Mass.-based Boston Scientific’s TheraSphere treatment, […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, Oncology Tagged With: Boston Scientific

TriSalus enrolls first patient in pressure-enabled drug delivery trial for treating melanoma

September 7, 2021 By Sean Whooley

TriSalus-logo

TriSalus Life Sciences announced today that it enrolled the first patient in its clinical study of a treatment for metastatic uveal melanoma. The PERIO-01 clinical study evaluates SD-101, an investigational toll-like receptor 9 (TLR9) agonist in adults with metastatic uveal melanoma through intravascular administration into uveal melanoma liver metastasis lesions in combination with checkpoint inhibitors […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, Oncology Tagged With: trisaluslifesciences

Novocure plummets on missed Q2 projections

July 29, 2021 By Sean Whooley

novocure logo

Novocure (NSDQ:NVCR) shares took a dive today on second-quarter results that came up short of the consensus forecast. NVCR shares were down -11.7% at $160.67 in mid-afternoon trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.9% on the day. The St. Helier, N.J.-based […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Oncology, Wall Street Beat Tagged With: NovoCure

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 32
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS